# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-25-033316
Filing Date
2025-04-18
Accepted
2025-04-18 15:00:39
Documents
20
Period of Report
2025-06-02

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PROXY STATEMENT | ea0237916-01.htm iXBRL | DEF 14A | 1348140
6 | GRAPHIC | toruka_logo.jpg | GRAPHIC | 78491
7 | GRAPHIC | tproxy_001.jpg | GRAPHIC | 1059426
8 | GRAPHIC | tproxy_002.jpg | GRAPHIC | 1098054
| Complete submission text file | 0001213900-25-033316.txt |  | 8116372

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
2 | XBRL SCHEMA FILE | orka-20250602.xsd | EX-101.SCH | 13456
3 | XBRL DEFINITION FILE | orka-20250602_def.xml | EX-101.DEF | 6760
4 | XBRL LABEL FILE | orka-20250602_lab.xml | EX-101.LAB | 43262
5 | XBRL PRESENTATION FILE | orka-20250602_pre.xml | EX-101.PRE | 11203
22 | EXTRACTED XBRL INSTANCE DOCUMENT | ea0237916-01_htm.xml | XML | 601983

Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-22873 | Film No.: 25850257
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)